



(43) International Publication Date
6 June 2013 (06.06.2013)

(10) International Publication Number
WO 2013/082003 A1

(51) International Patent Classification:

A61K 31/4196 (2006.01) *A61P 31/14* (2006.01)
A61K 31/513 (2006.01) *A61K 9/20* (2006.01)

(21) International Application Number:

PCT/US2012/066605

(22) International Filing Date:

27 November 2012 (27.11.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/564,500 29 November 2011 (29.11.2011) US
PCT/US2012/055621

14 September 2012 (14.09.2012) US

61/707,459 28 September 2012 (28.09.2012) US

13/661,509 26 October 2012 (26.10.2012) US

(71) Applicant: GILEAD PHARMASSET LLC [US/US];
C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
CA 94404 (US).

(72) Inventors: CLEARY, Darryl, G.; 6410 Falconbridge
Road, Chapel Hill, NC 27517 (US). REYNOLDS,
Charles, J.; 2301 Pines Crossing Way, Greenville, NC
27858 (US). BERREY, Miriam, Michelle; 3915 Chippen-
ham Road, Durham, NC 27707 (US). HINDES, Robert,
G.; 53 Durham Road, Skillman, NJ 08558 (US). SY-
MONDS, William, T.; 301 Mission Street, Unit 45f, San
Francisco, CA 94105 (US). RAY, Adrian, S.; 19 Pilot
Circle, Redwood City, CA 94065 (US). MO, Hongmei;
972 Clara Drive, Palo Alto, CA 94303 (US). HEBNER,
Christy, M.; 2103 Shirley Road, Belmont, CA 94402
(US). OLIYAI, Reza; 1504 Alturas Drive, Burlingame,
CA 94010 (US). ZIA, Vahid; 53 Maple Way, San Carlos,

CA 94070 (US). STEFANIDIS, Dimitrios; 278 Monroe
Drive, Apartment 14, Mountain View, CA 94040 (US).
PAKDAMAN, Rowchanak; 16 Wildwood Avenue, San
Carlos, CA 94070 (US). CASTEEL, Melissa, Jean; 749
Lexington Way, Burlingame, CA 94010 (US).

(74) Agents: RUSSO, Alicia, A. et al.; Fitzpatrick, Cella, Har-
per & Scinto, 1290 Avenue Of The Americas, New York,
NY 10104-3800 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS

(57) Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.



WO 2013/082003 A1